Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;151(3):261-269.
doi: 10.1111/imm.12748. Epub 2017 May 24.

Pathogenesis of vascular leak in dengue virus infection

Affiliations
Review

Pathogenesis of vascular leak in dengue virus infection

Gathsaurie Neelika Malavige et al. Immunology. 2017 Jul.

Abstract

Endothelial dysfunction leading to vascular leak is the hallmark of severe dengue. Vascular leak typically becomes clinically evident 3-6 days after the onset of illness, which is known as the critical phase. This critical phase follows the period of peak viraemia, and lasts for 24-48 hr and usually shows rapid and complete reversal, suggesting that it is likely to occur as a result of inflammatory mediators, rather than infection of the endothelium. Cytokines such as tumour necrosis factor-α, which are known to be elevated in the critical phase of dengue, are likely to be contributing factors. Dengue NS1, a soluble viral protein, has also been shown to disrupt the endothelial glycocalyx and thus contribute to vascular leak, although there appears to be a discordance between the timing of NS1 antigenaemia and occurrence of vascular leak. In addition, many inflammatory lipid mediators are elevated in acute dengue viral infection such as platelet activating factor (PAF) and leukotrienes. Furthermore, many other inflammatory mediators such as vascular endothelial growth factor and angiopoietin-2 have been shown to be elevated in patients with dengue haemorrhagic fever, exerting their action in part by inducing the activity of phospholipases, which have diverse inflammatory effects including generation of PAF. Platelets have also been shown to significantly contribute to endothelial dysfunction by production of interleukin-1β through activation of the NLRP3 inflammasome and also by inducing production of inflammatory cytokines by monocytes. Drugs that block down-stream immunological mediator pathways such as PAF may also be beneficial in the treatment of severe disease.

Keywords: NS1 antigen; dengue; lipid mediators; platelet activating factor; vascular leak.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Model of endothelial dysfunction in dengue infection. Cytokines and tumour necrosis factor‐α (TNFα) produced by dengue virus (DENV) ‐infected monocytes, dendritic cells (DCs) and macrophages possibly cause endothelial activation and also activate nuclear factor‐κB (NFκB) to induce platelet‐activating factor (PAF) production. LPS present in the blood by possible microbial translocation amplifies this effect and also induces PAF production from these cells. Vascular endothelial growth factor (VEGF) produced by mast cells and other cells act on secretory phospholipase A2 (sPLA2) to induce production of PAF and mast cells are also a possible source of sPLA2, which leads to PAF production. Platelets, which are also directly infected by the DENV, produce many cytokines by forming platelet monocyte aggregates. Platelet‐derived microparticles, are an important source of interleukin‐1β (IL‐1β), which are produced by activation of the NLRP3 inflammasome. NS1 could also act through Toll‐like receptor 4 (TLR4) inducing phospholipases to generate PAF from phospholipids and also induce production of many inflammatory cytokines, which contribute to the ‘cytokine storm’. Ang‐2 produced by endothelial activation also in turn activated sPLA2 to induce PAF production. Dengue NS1 hexamers bind to the endothelial glycocalyx, resulting in loss of sialic acid. NS1 also leads to the cleavage of heparan sulphate from the endothelial glycocalyx.

References

    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al The global distribution and burden of dengue. Nature 2013; 496:504–7. - PMC - PubMed
    1. Mortality GBD , Causes of Death C . Global, regional, and national life expectancy, all‐cause mortality, and cause‐specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388:1459–544. - PMC - PubMed
    1. Deen J. The dengue vaccine dilemma: balancing the individual and population risks and benefits. PLoS Med 2016; 13:e1002182. - PMC - PubMed
    1. Fernando S, Wijewickrama A, Gomes L, Punchihewa CT, Madusanka SD, Dissanayake H et al Patterns and causes of liver involvement in acute dengue infection. BMC Infect Dis 2016; 16:319. - PMC - PubMed
    1. Lee TH, Lee LK, Lye DC, Leo YS. Current management of severe dengue infection. Expert Rev Anti Infect Ther 2017; 15:67–78. - PubMed

Publication types

MeSH terms